NCT02123706: A Phase IIa, Single-blind, Placebo-controlled, Crossover, Multi-center, Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Heart Failure of Non-ischemic Etiology |
|
|
| Recruiting | 2a | 20 | US | Human Allogeneic Mesenchymal Stem Cells, Mesenchymal Stem Cells, Marrow Stromal Cells, Placebo, Lactated Ringer's Solution | Stemedica Cell Technologies, Inc., CardioCell, LLC; A Stemedica Company | Non-ischemic Heart Failure | 06/16 | 06/16 | | |
| Completed | 2 | 117 | Europe | MAGIC EXPLORER (Biotronik AG), PLEON EXPLORER (Biotronik AG) | Flanders Medical Research Program, Biotronik SE & Co. KG | Breast Cancer | | 01/07 | | |
NCT02290483: Intra-arterial Autologous Bone-marrow Mononuclear Cells Infusion for Acute Ischemic Stroke |
|
|
| Recruiting | 2 | 76 | Europe | Autologous bone marrow mononuclear stem cells, No intervention | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud, Iniciativa Andaluza en Terapias Avanzadas | Stroke | 03/19 | 09/19 | | |
NCT00956332: Safety Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia |
|
|
| Active, not recruiting | 1/2 | 28 | RoW | MultiGeneAngio | MultiGene Vascular Systems Ltd. | Peripheral Arterial Disease, Peripheral Vascular Disease, Critical Limb Ischemia | 08/11 | 05/26 | | |
